Related Experiment Video

Updated: Jun 24, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

[Bevacizumab in the treatment of non-small cell lung cancer]

Aija Knuuttila1, Annamari Rouhos, Eeva-Maija Karjalainen

  • 1Helsingin yliopisto, ja HYKS:n keuhkosairauksien klinikka, PL 340, 00029 HUS.

Duodecim; Laaketieteellinen Aikakauskirja
|April 11, 2009
PubMed

Insights

Bevacizumab shows promise in treating non-small cell lung cancer when combined with chemotherapy. However, current evidence does not support its use as a standard lung cancer therapy.

Area of Science:

  • Oncology
  • Medical research

Background:

  • Current treatments for advanced non-small cell lung cancer (NSCLC) primarily slow disease progression.
  • No curative treatments are currently available for advanced or metastatic NSCLC.

Purpose of the Study:

  • To evaluate the efficacy of Bevacizumab, a novel antiangiogenetic agent, in treating advanced or metastatic non-small cell lung cancer.
  • To assess the potential of Bevacizumab to improve treatment outcomes and prognosis in NSCLC patients.

Main Methods:

  • Two randomized studies were conducted to investigate the effects of Bevacizumab.
  • Bevacizumab was administered in combination with a cytotoxic platinum agent to a selected patient group.

Main Results:

  • The combination of Bevacizumab with a cytotoxic platinum agent demonstrated increased therapeutic effectiveness in a selected patient group.
  • The studies provided preliminary data on the efficacy of Bevacizumab in NSCLC treatment.

Conclusions:

  • While Bevacizumab shows potential in combination therapy for NSCLC, current scientific evidence is insufficient to establish it as a standard treatment.
  • Further research is needed to determine the optimal role and long-term impact of Bevacizumab in NSCLC management.

More Related Videos

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring08:45

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Published on: November 13, 2012

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.